iMDx Q2 Loss Widens to $11.3M; FDA Seeks Additional Data on GraftAssureDx

summarizeSummary

A wider Q2 loss and an FDA request for more data on lead candidate GraftAssureDx push back the approval timeline. With $18.7 million in cash and a $10 million quarterly burn rate, the runway is tightening.

check_boxKey Events · Earnings and Guidance · IMDX

• Q2 Net Loss Widens to $11.3M

  The net loss reached $11.3 million ($0.31/share), compared with $4.3 million in Q1, largely due to a $2.3 million non-cash contingent consideration charge. Revenue was a mere $239,000.

• FDA Issues Additional Information Request

  After completing its current review phase, the FDA issued an AIR for GraftAssureDx, giving the company 180 days to respond. Management anticipates one more FDA meeting before Q4 2026.

• Cash Runway Tightens

  Cash and equivalents dropped to $18.7 million from $29.4 million at the start of Q2. The quarterly cash burn of approximately $10 million implies less than two quarters of runway at current spending levels.

• Non-Cash Contingent Consideration Loss

  A $2.3 million non-cash loss from the fair value revaluation of acquisition-related earnout liabilities inflated the reported operating loss.

auto_awesomeAnalysis · IMDX · Life Sciences

A widening Q2 net loss of $11.3 million, up from $4.3 million in Q1, was fueled by a $2.3 million non-cash charge tied to the revaluation of contingent consideration. With revenue at just $239,000, the pre-revenue status remains stark. Adding to the pressure, the FDA issued an Additional Information Request for GraftAssureDx, which extends the review timeline by up to 180 days. Although management calls this routine, it postpones potential commercialization and injects fresh uncertainty. Cash stands at $18.7 million against a quarterly burn of roughly $10 million, leaving less than two quarters of runway at current spending—raising the stakes for the FDA outcome and future financing.